Diligence memo · auto-generated · as of July 2, 2026
Adgero Biopharmaceuticals Holdings, Inc.
Adgero Biopharmaceuticals Holdings, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Adgero Biopharmaceuticals Holdings, Inc. operates in Biotechnology, based in PRINCETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Adgero Biopharmaceuticals Holdings, Inc. has raised $3.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2016-04-08.
Most recent recorded round closed around 2016-08-31.
Valuation (modeled)modeled
Provath models Adgero Biopharmaceuticals Holdings, Inc. at approximately $20M (range $330K–$160M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.29× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 9.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 6.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 37% of Biotechnology peers (4293 compared).
Modeled value ranks above 29% of those peers.
Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.